Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Neurocrine Biosciences begins phase I/II trial of NBI-77860

Dec. 12, 2014

Alize Pharma reports phase I findings on AZP-531

Dec. 11, 2014

Endo acquires rights to Natesto testosterone nasal gel

Dec. 11, 2014

Euroscreen successfully completes phase I study of ESN-364

Dec. 10, 2014

FDA approves Xgeva for hypercalcemia of malignancy

Dec. 9, 2014

Lutinus for luteal supplementation launched in Japan

Dec. 9, 2014

Sichuan Haisco Pharmaceutical patents novel SGLT2 inhibitors

Dec. 9, 2014

ProMetic to evaluate PBI-4050 in new indication

Dec. 9, 2014

Results for anacetrapib from phase III REALIZE study

Dec. 5, 2014

Prothena reports phase I/II data for NEOD-001 in AL amyloidosis and initiates phase III trial

Dec. 5, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...